Reply to the Letter to the Editor "Reflections on the statistical methodology in nivolumab and ipilimumab therapy research" by S. Yang

Ann Oncol. 2024 Sep;35(9):827-828. doi: 10.1016/j.annonc.2024.07.719.

Authors

I Melero¹, S Soleymani², M Tschaika³, A B El-Khoueiry⁴

Affiliations

¹ Department of Immunology, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain. Electronic address: imelero@unav.es.
² Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton.
³ Oncology Clinical Development, Bristol Myers Squibb, Princeton.
⁴ USC Norris Comprehensive Cancer Center, Los Angeles, USA.

PMID: 39214632
DOI: 10.1016/j.annonc.2024.07.719

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Humans
Ipilimumab* / therapeutic use
Nivolumab* / therapeutic use

Substances

Nivolumab
Ipilimumab
Antineoplastic Agents, Immunological